scholarly journals Genetic Profile of Adenoid Cystic Carcinomas (ACC) with High-Grade Transformation versus Solid Type

2010 ◽  
Vol 33 (5-6) ◽  
pp. 217-228 ◽  
Author(s):  
Ana Flávia Costa ◽  
Albina Altemani ◽  
Hedy Vékony ◽  
Elisabeth Bloemena ◽  
Florentino Fresno ◽  
...  

Background: ACC can occasionally undergo dedifferentiation also referred to as high-grade transformation (ACC-HGT). However, ACC-HGT can also undergo transformation to adenocarcinomas which are not poorly differentiated. ACC-HGT is generally considered to be an aggressive variant of ACC, even more than solid ACC. This study was aimed to describe the genetic changes of ACC-HGT in relation to clinico-pathological features and to compare results to solid ACC.Methods: Genome-wide DNA copy number changes were analyzed by microarray CGH in ACC-HGT, 4 with transformation into moderately differentiated adenocarcinoma (MDA) and two into poorly differentiated carcinoma (PDC), 5 solid ACC. In addition, Ki-67 index and p53 immunopositivity was assessed.Results: ACC-HGT carried fewer copy number changes compared to solid ACC. Two ACC-HGT cases harboured a breakpoint at 6q23, near the cMYB oncogene. The complexity of the genomic profile concurred with the clinical course of the patient. Among the ACC-HGT, p53 positivity significantly increased from the conventional to the transformed (both MDA and PDC) component.Conclusion: ACC-HGT may not necessarily reflect a more advanced stage of tumor progression, but rather a transformation to another histological form in which the poorly differentiated forms (PDC) presents a genetic complexity similar to the solid ACC.

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii351-iii351
Author(s):  
Frank Dubois ◽  
Ofer Shapira ◽  
Noah Greenwald ◽  
Travis Zack ◽  
Jessica W Tsai ◽  
...  

Abstract BACKGROUND Driver single nucleotide variants (SNV) and somatic copy number aberrations (SCNA) of pediatric high-grade glioma (pHGGs), including Diffuse Midline Gliomas (DMGs) are characterized. However, structural variants (SVs) in pHGGs and the mechanisms through which they contribute to glioma formation have not been systematically analyzed genome-wide. METHODS Using SvABA for SVs as well as the latest pipelines for SCNAs and SNVs we analyzed whole-genome sequencing from 174 patients. This includes 60 previously unpublished samples, 43 of which are DMGs. Signature analysis allowed us to define pHGG groups with shared SV characteristics. Significantly recurring SV breakpoints and juxtapositions were identified with algorithms we recently developed and the findings were correlated with RNAseq and H3K27ac ChIPseq. RESULTS The SV characteristics in pHGG showed three groups defined by either complex, intermediate or simple signature activities. These associated with distinct combinations of known driver oncogenes. Our statistical analysis revealed recurring SVs in the topologically associating domains of MYCN, MYC, EGFR, PDGFRA & MET. These correlated with increased mRNA expression and amplification of H3K27ac peaks. Complex recurring amplifications showed characteristics of extrachromosomal amplicons and were enriched in coding SVs splitting protein regulatory from effector domains. Integrative analysis of all SCNAs, SNVs & SVs revealed patterns of characteristic combinations between potential drivers and signatures. This included two distinct groups of H3K27M DMGs with either complex or simple signatures and different combinations of associated variants. CONCLUSION Recurrent SVs associate with signatures shaped by an underlying process, which can lead to distinct mechanisms to activate the same oncogene.


2003 ◽  
Vol 25 (3) ◽  
pp. 103-114 ◽  
Author(s):  
Harald Blegen ◽  
John S. Will ◽  
B. Michael Ghadimi ◽  
Hesed‐Padilla Nash ◽  
Anders Zetterberg ◽  
...  

In order to explore whether specific cytogenetic abnormalities can be used to stratify tumors with a distinctly different clinical course, we performed comparative genomic hybridization (CGH) of tumors from patients who were diagnosed with metastatic disease after an interval of less than 2 years or who remained free from distant metastases for more than 10 years. All patients presented with distant metastases after mastectomy indicating that none of the patients in this study was cured and free of remaining tumor cells. Tumors in the group of short‐term survivors showed a higher average number of chromosomal copy alterations compared to the long‐term survivors. Of note, the number of sub‐chromosomal high‐level copy number increases (amplifications) was significantly increased in the group of short‐term survivors. In both short‐ and long‐term survivors recurrent chromosomal gains were mapped to chromosomes 1q, 4q, 8q, and 5p. Copy number changes that were more frequent in the group of short‐term survivors included gains of chromosome 3q, 9p, 11p and 11q and loss of 17p. Our results indicate that low‐ and high grade malignant breast adenocarcinomas are characterized by a specific pattern of chromosomal copy number changes. Furthermore, immunohistochemical evaluation of the expression levels of Ki‐67, p27KIP1, p21WAF1, p53, cyclin A and cyclin E revealed a correlation between increased proliferative activity and poor outcome.


2009 ◽  
Vol 84 (3) ◽  
pp. 339-350 ◽  
Author(s):  
Martin F. Arlt ◽  
Jennifer G. Mulle ◽  
Valerie M. Schaibley ◽  
Ryan L. Ragland ◽  
Sandra G. Durkin ◽  
...  

2013 ◽  
Author(s):  
Olafur A. Stefansson ◽  
Sebastian Moran ◽  
Antonio Gomez ◽  
Sergi Sayols Puig ◽  
Jorunn Eyfjord ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2946-2946
Author(s):  
Justyna Rawluk ◽  
Dietmar Pfeifer ◽  
Milena Pantic ◽  
Hendrik Veelken

Abstract Chronic lymphocytic leukemia (CLL) is a heterogeneous disease characterized by different recurrent chromosomal aberrations with prognostic significance. Therefore, convenient genome-wide assays to identify genetic changes with high accuracy are required to assess the risk category of an individual patient, and to identify genetic mechanisms underlying the malignant transformation. Array-based CGH with custom-made chips has been proposed for this purpose (Schwaenen et al., 2004). We analyzed unselected peripheral blood cells from 50 consecutive CLL patients (33 with mutated IgVH genes) for the presence of genetic changes using Affymetrix 10k and 50k SNP mapping arrays that allow copy number analysis with a mean intermarker distance 300 kb and 60 kb, respectively. The detection limit of the assay with respect to tumor cell content was 25 to 40 % as assessed by validation experiments with a commercially available panel of FISH probes for typical recurrent CLL aberrations. 14 cases (28%) failed to show any detectable abnormalities. Among the common prognostically important aberrations, we readily identified del13q14 in 26 (52%), trisomy 12 in 9 (18%), del11q22 in 6 (12%), and del17p13 in 3 cases (6%). In 9 cases, additional losses in 17q (3 cases), 14q (2 cases), 5q (2 cases), 1q, 18p and 20q were detected. Likewise, multiple gains like trisomy 3, dup17q and dup2p (2 cases) were diagnosed. In addition to their convenient detection, size and extent of genomic aberrations can be defined with high resolution due to the precise positional information of the SNPs: In 2 out of 6 patients with a del11q22, in which deletion of the ATM (ataxia-telangiectasia mutated) gene is thought to represent the critical event, the ATM gene was present, but a 1Mb deletion around the RDX (radixin) gene was revealed. These deletions were missed by FISH analysis with ATM-spanning probes. Similarly, TP53 was still present in 1 of 3 patients with del17p13, despite the common assumption that this deletion causes the loss of a TP53 allele. An observed gain of 2p16 could be narrowed down to a 3Mb region containing the REL gene. Overexpression of REL may contribute to resistance to DNA-damage-induced apoptosis in CLL cells in vitro (Vallat et al., 2003). Finally, both the 10k and 50k SNP arrays showed the extent of the most frequent del13q14 in a wide range with a size distribution of 500kb to over 30Mb. However, for a more reliable detection of the del13q14 core region, the 50k array may be preferable to the 10k version, since this region is covered by 34 compared to 4 SNPs, respectively. Unexpectedly, 3 of 6 cases with a homozygous del13q14 showed loss of heterozygosity (LOH) associated with a normal copy number distal to the del13q14 extending to the telomere. A similar phenomenon has recently been described in AML patients (Raghavan et al., 2005) and can be explained by a somatic recombination event. Preliminary analyses demonstrated additional large regions of homozygosity ranging from 3 to over 20Mb on various chromosomes in at least 12 CLL cases. In conclusion, genomic profiling with Affymetrix SNP microarrays is an efficient screening method for simultaneous genome-wide detection of submicroscopic aberrations. Information on genotype with dosis information reveals hitherto undetected regions of homozygosity that may harbor imprinted genes or loss-of-function alleles with importance for the pathogenesis of CLL.


2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 624-624
Author(s):  
Thomas Yang Sun ◽  
Paul Van Hummelen ◽  
Brock Martin ◽  
Charlie Xia ◽  
Hojoon Lee ◽  
...  

624 Background: Grade 3 neuroendocrine neoplasms (G3 NENs), if poorly differentiated, have a median survival of only 10-19 months. Little is known regarding their underlying genomics. Methods: We applied multiomics analysis to 46 cases of G3 NEN that included copy number analysis, whole exome, and transcriptomic sequencing. Results: Of the 46 unique cases, 17 were lung, 16 gastroenteropancreatic (GEP), 13 other; 5 well-differentiated, 39 poorly differentiated and 2 mixed. Using a multivariate Cox model, we found histology characteristics (including differentiation, Ki67 and mitotic index) did not correlate with changes in overall survival (OS). The clinical variables that did correlate with OS included: number of lines of treatment (hazard ratio for death [HR], 0.72; p < 0.05), GEP primary site (HR, 5.36; p < 0.005), and non-resected primary tumor (HR, 14.52; p < 0.001). Two copy number changes were associated with worse prognosis: focal deletion 22q13 (HR, 10.23; p < 0.005), and arm amplification 19q (HR, 7.09; p < 0.01). The median OS of the top quartile compared to the rest for 22q13 deletion carriers was 9.9 months vs. 24 months, and for 19q amplification carriers was 8.7 months vs. 36.7 months. We estimated a median tumor mutation burden (TMB) of 3.7 mutations/Mb, with 20% (8/40) of patients showing high TMB ( > 10 mutations/Mb). The top five mutated genes were USH2A, RB1, APC, TP53, and MUC16. We also observed high transcriptomic similarity across all NENs regardless of their site of origin. Conclusions: We identified two copy number changes that can serve as predictive biomarkers in G3 NENs, as they confer an increased risk of death by as high as 10x to the carriers. Further, G3 NENs are characterized by a distinct group of somatic mutations, and a significant number have high tumor mutation burden. Lastly, G3 NENs across different organs were relatively homogeneous in expression profile.


2008 ◽  
Vol 7 (1) ◽  
pp. 48 ◽  
Author(s):  
Stine H Kresse ◽  
Magne Skårn ◽  
Hege O Ohnstad ◽  
Heidi M Namløs ◽  
Bodil Bjerkehagen ◽  
...  

Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 168
Author(s):  
Elena Ioana Braicu ◽  
Andreas du Bois ◽  
Jalid Sehouli ◽  
Julia Beck ◽  
Sonia Prader ◽  
...  

Background: Chromosomal instability, a hallmark of cancer, results in changes in the copy number state. These deviant copy number states can be detected in the cell-free DNA (cfDNA) and provide a quantitative measure of the ctDNA levels by converting cfDNA next-generation sequencing results into a genome-wide copy number instability score (CNI-Score). Our aim was to determine the role of the CNI-Score in detecting epithelial ovarian cancer (EOC) and its role as a marker to monitor the response to treatment. Methods: Blood samples were prospectively collected from 109 patients with high-grade EOC. cfDNA was extracted and analyzed using a clinical-grade assay designed to calculate a genome-wide CNI-Score from low-coverage sequencing data. Stored data from 241 apparently healthy controls were used as a reference set. Results: Comparison of the CNI-Scores of primary EOC patients versus controls yielded sensitivities of 91% at a specificity of 95% to detect OC, respectively. Significantly elevated CNI-Scores were detected in primary (median: 87, IQR: 351) and recurrent (median: 346, IQR: 1891) blood samples. Substantially reduced CNI-Scores were detected after primary debulking surgery. Using a cut-off of 24, a diagnostic sensitivity of 87% for primary and recurrent EOC was determined at a specificity of 95%. CNI-Scores above this threshold were detected in 21/23 primary tumor (91%), 36/42 of platinum-eligible recurrent (85.7%), and 19/22 of non-platinum-eligible recurrent (86.3%) samples, respectively. Conclusion: ctDNA-quantification based on genomic instability determined by the CNI-Score was a biomarker with high diagnostic accuracy in high-grade EOC. The applied assay might be a promising tool for diagnostics and therapy monitoring, as it requires no a priori information about the tumor.


Sign in / Sign up

Export Citation Format

Share Document